Novozymes AS (NVZMY)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Novozymes AS (NVZMY) is down 8.2% since the beginning of the year. At $58 per share, NVZMY is trading 24.1% below its 52-week high of $76. Investors who bought $1,000 worth of NVZMY shares 5 years ago would now be looking at an investment worth $856.

Novozymes AS (NVZMY) has returned -8.20% so far this year and -16.45% over the past 12 months. Over the last ten years, NVZMY has returned 3.31% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.

Based on dividend-adjusted daily data since Jul 13, 2007, NVZMY's average daily return is +0.03%, while the average monthly return is +0.42%. At this rate, an investment would double in approximately 13.8 years.

Historically, 56% of months were positive and 44% were negative. The best month was Jul 2010 with a return of +20.3%, while the worst month was Dec 2011 at -81.1%. The longest winning streak lasted 8 consecutive months, and the longest losing streak was 5 months.

On a daily basis, NVZMY closed higher 49% of trading days. The best single day was Oct 17, 2008 with a return of +26.9%, while the worst single day was Dec 12, 2011 at -80.5%.

Novozymes AS has an annualized alpha of 0.69%, beta of 0.60, and R2 of 0.10 versus S&P 500 Index. Calculated based on daily prices since July 16, 2007.

• This stock participated in 95.02% of S&P 500 Index downside but only 46.38% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.60 may look defensive, but with R2 of 0.10 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.10 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

NVZMY ranks 14 for risk / return — in the bottom 14% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The table below present risk-adjusted performance metrics for Novozymes AS (NVZMY) and compare them to S&P 500 Index.

Novozymes AS provided a 1.77% dividend yield over the last twelve months, with an annual payout of $1.02 per share.

The table displays the monthly dividend distributions for Novozymes AS. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Novozymes AS. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Novozymes AS was 86.29%, occurring on Aug 2, 2012. The portfolio has not yet recovered.

The current Novozymes AS drawdown is 60.49%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Novozymes AS over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Novozymes AS is priced in the market compared to other companies in the Specialty Chemicals industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.